I-SENS LAUNCH DUAL BLOOD GLUCOSE AND KETONE MONITORING SYSTEM
MAY 4, 2019 @ 12.16 PM
I-Sens, recently launched its CareSens Dual blood glucose and ß-ketone monitoring system.
The dual function of CareSens will help diabetics achieve the right balance in checking their daily blood glucose and ketone levels. High levels of ketones in the bloodstream is a common complication of diabetes, which left untreated, can lead to ketoacidosis and even coma.
The launch aimed to highlight the importance of a healthy lifestyle, as Malaysia now has the highest rate of diabetes in Asia. Based on statistics from National Diabetes Institute (NADI), there are over 2.5 million adults with diabetes in Malaysia. Furthermore, NADI’s data suggests that nearly half of Malaysians are unaware that they have diabetes.
“Very often, patients with Type 2 diabetes carry on with life without any symptoms until they experience a heart attack, stroke, kidney failure, go blind or require an amputation,” said Professor Dr Nor Azmi Kamaruddin, Head of Diabetes & Endocrinology, National University of Malaysia (UKM) Medical Centre.
Dr. Hakhyun Nam, President & Co-Founder of i-SENS, Inc. stated that the event provided a clear call-to-action for the public to get their blood glucose levels checked and diabetes patients to seek the appropriate medical treatment.
CareSens Dual’s other USPs to make diabetes care easier include a large display and auto-backlight LCD screen, beneficial for diabetic patients who often develop vision impairment. Thanks to the system’s advanced technology, it provides fast and accurate reading with less blood sample required. The device is innovated to be mobile, convenient and easy for diabetics to check their readings even on-the-go.
CareSens Dual features handy connectivity via the SmartLog app where data readings can be sent to the patients’ smartphone for a more comprehensive day-to-day monitoring.
CareSens Dual will be available at selected Guardian pharmacies nationwide from June onwards.
Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
The culture of colourism: The obsession with lighter skin tones driving opportunities in the skin lighteners market
Arson, animal cruelty and lack of remorse - traits of personality disorders to look out for in a person
Astrazeneca signs MoA with InvestKL to improve access to healthcare, explore digital transformation in the management of diseases